Loading...
VTYX logo

Ventyx Biosciences, Inc.NasdaqGS:VTYX Stock Report

Market Cap US$1.0b
Share Price
US$14.00
US$13.29
5.4% overvalued intrinsic discount
1Y803.2%
7D0.2%
1D
Portfolio Value
​
View

Ventyx Biosciences, Inc.

NasdaqGS:VTYX Stock Report

Market Cap: US$1.0b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Ventyx Biosciences (VTYX) Stock Overview

A clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. More details

VTYX fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Risk Analysis

Makes less than USD$1m in revenue ($0)

Currently unprofitable and not forecast to become profitable over the next 3 years

Volatile share price over the past 3 months compared to the US market


VTYX Community Fair Values

Create Narrative

See what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Ventyx Biosciences, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Ventyx Biosciences
Historical stock prices
Current Share PriceUS$14.00
52 Week HighUS$25.00
52 Week LowUS$0.78
Beta1.27
1 Month Change0.36%
3 Month Change60.55%
1 Year Change803.23%
3 Year Change-66.26%
5 Year Changen/a
Change since IPO-33.40%

Recent News & Updates

Recent updates

Seeking Alpha • Nov 11

Ventyx Biosciences: Why Caution Should Remain

Summary Ventyx Biosciences reported Phase 2 results for VTX3232, showing strong anti-inflammatory effects as secondary endpoints. VTYX's VTX3232 lowered hsCRP and IL-6, suggesting cardiometabolic benefits, but trial design and biomarker specificity raise concerns about translatability. A short cash runway and heavy reliance on VTX3232's success create significant risk; future trial outcomes will heavily impact the stock. Read the full article on Seeking Alpha
Analysis Article • Sep 23

Is Ventyx Biosciences (NASDAQ:VTYX) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analysis Article • May 05

Is Ventyx Biosciences (NASDAQ:VTYX) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Nov 14

We Think Ventyx Biosciences (NASDAQ:VTYX) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha • Nov 04

Ventyx Biosciences: Ready To Escape "The Crash Cycle"

Summary Based on quatitative factors, Ventyx is similar to other issues I've rated here on Seeking Alpha that have outpaced the market. Because of its extremely low valuation and strong financials, I see obvious potential for Ventyx to outperform the market. Despite past troubles, management actions are addressing issues, though risks include volatility and the risk that drugs will not go commercial. Read the full article on Seeking Alpha
Analysis Article • Jul 12

Is Ventyx Biosciences (NASDAQ:VTYX) In A Good Position To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Jul 01

Ventyx Biosciences: Slim Chances In A Fat Market (Rating Downgrade)

Summary Ventyx Biosciences, Inc. is focusing on advancing VTX3232 for obesity and Parkinson's, with early but promising preclinical results in obesity. The drug VTX3232 has shown potential in preclinical trials, but its application in Parkinson’s faces uncertainty due to mixed evidence about the role of NLRP3. Despite a strong balance sheet, Ventyx’s prospects in ulcerative colitis and Crohn's disease face stiff competition and historical clinical failures. Due to the very low odds of clinical and market success, the current low stock prices are seen as a sign to sell rather than buy. Read the full article on Seeking Alpha
Seeking Alpha • Mar 12

Ventyx Pivots To Obesity Amid Transformation

Summary Ventyx's stock plummeted from over $30/share to $2/share after disappointing data for VTX958, prompting workforce reductions. VTX3232 shows promise in preclinical trials for obesity and Parkinson's, with a trial on obesity planned for the second half of the year. Financially, VTYX is stable, with a cash runway extending into the second half of 2026 after recent PIPE financing. Investment recommendation: Hold Ventyx due to high volatility and risk, but it offers potential high returns for diversified portfolios seeking alpha. Read the full article on Seeking Alpha
Analysis Article • Feb 15

Here's Why We're Watching Ventyx Biosciences' (NASDAQ:VTYX) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Seeking Alpha • Jan 18

Ventyx: Too Risky Right Now After Some Poor Data

Summary Ventyx Biosciences has a mid-stage pipeline targeting inflammatory diseases, with lead assets VTX958, VTX002, and VTX2735. Phase 1 data for VTX958 showed high selectivity and excellent safety profile, but phase 2 trial results did not meet internal targets for further development in psoriasis. VTX002 demonstrated positive phase 2 data in ulcerative colitis, achieving primary and secondary endpoints and outperforming other molecules in clinical and endoscopic remission. Read the full article on Seeking Alpha
Analysis Article • Sep 21

Companies Like Ventyx Biosciences (NASDAQ:VTYX) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysis Article • Jun 07

Ventyx Biosciences (NASDAQ:VTYX) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Feb 20

We're Not Very Worried About Ventyx Biosciences' (NASDAQ:VTYX) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. By way of example, Ventyx...

Shareholder Returns

VTYXUS PharmaceuticalsUS Market
7D0.2%-3.8%1.4%
1Y803.2%37.7%25.7%

Return vs Industry: VTYX exceeded the US Pharmaceuticals industry which returned 22.2% over the past year.

Return vs Market: VTYX exceeded the US Market which returned 18.2% over the past year.

Price Volatility

Is VTYX's price volatile compared to industry and market?
VTYX volatility
VTYX Average Weekly Movement14.9%
Pharmaceuticals Industry Average Movement10.4%
Market Average Movement7.2%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.1%

Stable Share Price: VTYX's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: VTYX's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201883Raju Mohanventyxbio.com

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for Crohn’s disease. It is also developing Tamuzimod, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome.

Ventyx Biosciences, Inc. Fundamentals Summary

How do Ventyx Biosciences's earnings and revenue compare to its market cap?
VTYX fundamental statistics
Market capUS$1.00b
Earnings (TTM)-US$106.61m
Revenue (TTM)n/a
0.0x
P/S Ratio
-9.4x
P/E Ratio

Is VTYX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
VTYX income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$106.61m
Earnings-US$106.61m

Last Reported Earnings

Sep 30, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-1.49
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did VTYX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/03/05 03:24
End of Day Share Price 2026/03/03 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Ventyx Biosciences, Inc. is covered by 3 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hiroshi ShibutaniGoldman Sachs
Michael YeeJefferies LLC
Andrew TsaiJefferies LLC